GenomOncology Platform to Integrate Genomenon Literature Engine Results

October 30, 2018
GenomOncology Platform to Integrate Genomenon Literature Engine Results
GenomOncology will integrate into its Molecular Tumor Board platform results from Genomenon’s Mastermind Genomic Search Engine, through a collaboration whose value was not disclosed. [enot-poloskun/Getty Images]

GenomOncology will integrate into its Molecular Tumor Board platform results from Genomenon’s Mastermind Genomic Search Engine, through a collaboration whose value was not disclosed.

The companies said their critically ilpartnership was designed to enable oncologists to access up-to-date genomic research as they make treatment decisions for their cancer patients.

Molecular Tumor Board is designed to support a fully integrated workflow—including case creation, “smart” content for clinicians based on their patient’s alterations, therapy and clinical trial recommendations, and generation of a report for sign-off by oncologists.

The platform includes automatic parsing and loading of any NGS panel, including whole exome-whole genome; as well as the ability to integrate immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), cytogenetics, and other clinical data elements, with the goal of applying its proprietary match algorithm to generate tailored therapy and clinical trial recommendations.

By incorporating Mastermind search results in Molecular Tumor Board, GemonOncology reasons, oncologists can quickly determine whether a patient’s mutation appears in previously-published studies, then quickly access the research, as they review results of an NGS panel. Search results are automated based on the patient’s specific set of alterations, according to the companies.

“We know oncologists need to make timely decisions for patients, but are extremely pressed for time and overwhelmed with the amount of information out there. Providing them tools to make that easier is critical, especially as the field of oncology continues to change rapidly. Integrating Genomenon’s Mastermind is one of the ways we are doing this,” GenomOncology Founder and CEO Manuel Glynias said in a statement.

Mastermind is designed to link data on DNA mutations from patients with citations from scientific publications, with the goal of understanding the clinical impact of each mutation. Mastermind aims to comprehensively identify all clinically relevant and prioritized articles, and to date has indexed nearly 6 million scientific articles covering every disease, gene and variant.

According to Genomenon, Mastermind offers the world’s largest index of medical articles cataloguing the genetic relationships between DNA and human diseases.

“Precision medicine is about putting the best tools, information, and knowledge about the patient’s tumor into the hands of the experts to provide the best medical treatment for cancer patients,” Genomenon CEO Mike Klein said. “We’re thrilled to be partnering with GenomOncology to make the most comprehensive and up-to-date cancer research available to oncologists when they are making treatment decisions.”